Measuring the biological effect of presurgical metformin treatment in endometrial cancer

British Journal of Cancer

Volumn 114, Issue 3, 2016, Pages 281-289

  Sivalingam, V N ^a   Kitson, S ^a   McVey, R ^b   Roberts, C ^c   Pemberton, P ^b   Gilmour, K ^d   Ali, S ^e   Renehan, A G ^a   Kitchener, H C ^a   Crosbie, E J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d TAMESIDE GENERAL HOSPITAL   (United Kingdom)

^e ROYAL OLDHAM HOSPITAL   (United Kingdom)

Author keywords

atypical endometrial hyperplasia; endometrial cancer; Ki 67; metformin; PI3K AKT mTOR phosphoproteins; presurgical window study

Indexed keywords

KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTIDIABETIC AGENT; C PEPTIDE; GLUCOSE BLOOD LEVEL; INSULIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BIOLOGICAL ACTIVITY; BODY MASS; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; GASTROINTESTINAL SYMPTOM; HOMEOSTASIS; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VERY ELDERLY; CANCER GRADING; CARCINOMA, ENDOMETRIOID; CLINICAL TRIAL; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; METABOLISM; MYOMETRIUM; NEOADJUVANT THERAPY; PATHOLOGY; PHOSPHORYLATION; PREOPERATIVE CARE; TREATMENT OUTCOME; TUMOR INVASION;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; C-PEPTIDE; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN RESISTANCE; KI-67 ANTIGEN; METFORMIN; MIDDLE AGED; MYOMETRIUM; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PREOPERATIVE CARE; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84956799580     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.453     Document Type: Article

References (44)

1. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, Ferlay J, Miranda JJ, Romieu I, Dikshit R, Forman D, Soerjomataram I. (2015). Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 16: 36-46.
2. Berstein LM, Iyevleva AG, Vasilyev D, Poroshina TE, Imyanitov EN. (2013). Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer. Cell Cycle 12: 3681-3688.
3. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca M, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, DeCensi A. (2012). Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30: 2593-2600.
4. Burzawa J, Schmeler K, Soliman P, Meyer L, Bevers M, Pustilnik T, Anderson M, Ramondetta L, Tortolero-Luna G, Urbauer D, Chang S, Gershenson D, Brown J, Lu K. (2011). Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 204: e1-e7.
5. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. (2010). Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 116: 92-98.
6. Crosbie E, Zwahlen M, Kitchener H, Egger M, Renehan A. (2010). Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-Analysis. Cancer Epidemiol Biomarkers Prev 19: 3119-3130.
7. Crosbie EJ, Roberts C, Qian W, Swart AM, Kitchener HC, Renehan AG. (2012). Body mass index does not influence post-Treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer 48: 853-864.
8. Cancer Research UK. (2014). Uterine (womb) cancer incidence statistics [Online], London. Available at http://www.cancerresearchuk.org/cancerinfo/.cancerstats/types/uterus/incidence/.(last accessed 5 May 2015).
9. DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN. (2014). Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 148: 81-90.
10. Dowsett M, Nielsen T, A'hern R, Bartlett J, Coombes R, Cuzick J, Ellis M, Henry L, Hugh J, Lively T, Mcshane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith I, Viale G, Zujewski J, Hayes D. (2011). Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103: 1656-1664.
11. Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Trialists I. (2005). Short-Term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11: 915s-918ss.
12. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'hern R, Salter J, Detre S, Hills M, Walsh G. (2007). Prognostic value of Ki67 expression after short-Term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99: 167-170.
13. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A'hern R. (2006). Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 12: 1024s-1030s.
14. Evans J, Donnelly L, Emslie-Smith A, Alessi D, Morris A. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
15. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, Macdonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. (2011). Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12: 489-495.
16. Friberg E, Orsini N, Mantzoros C, Wolk A. (2007). Diabetes mellitus and risk of endometrial cancer: a meta-Analysis. Diabetologia 50: 1365-1374.
17. Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. (2012). Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 31: 48-56.
18. Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. (2015). Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst. 107(3): djv006.
19. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. (2011). Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50: 81-98.
20. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie D, Pusztai L, Moulder-Thomson S, Dewar J, Thompson A. (2011). Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128: 783-794.
21. Hawkes AL, Quinn M, Gebski V, Armes J, Brennan D, Janda M, Obermair A. (2014). Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device / metformin / weight loss in endometrial cancer (feMME) trial. Contemp Clin Trials 39: 14-21.
22. Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, Van Der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J, Pollak M. (2014). A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17: 252-258.
23. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. (2014). Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 134: 607-614.
24. Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero IL. (2015). Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol 212: 479 e1-479 e10.
25. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625.
26. Liu T, Gao H, Yang M, Zhao T, Liu Y, Lou G. (2014). Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer. Tumour Biol 35: 5805-5814.
27. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
28. McCluggage WG, Soslow RA, Gilks CB. (2011). Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology 59: 786-788.
29. Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. (2014). Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 120: 2986-2995.
30. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, Albuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, ForouzanfarMH, Goto A, GreenMA, Gupta R,Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E. (2014). Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384: 766-781.
31. National Institute of Health. (2010). Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 4.0, DCTD, NCI, NIH, DHHS June 14 2010 [Online]. Available at http://evs.nci. nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference -5x7.pdf (last accessed 1 February 2015).
32. Niraula S, Dowling R, Ennis M, Chang M, Done S, Hood N, Escallon J, Leong W, Mccready D, Reedijk M, Stambolic V, Goodwin P. (2012). Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135: 521-530.
33. Nout RA, Bosse T, Creutzberg CL, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, Van Der Steen-Banasik EM, Van Eijk R, Ter Haar NT, Smit VT. (2012). Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation. Gynecol Oncol 126: 466-473.
34. Renehan A, Tyson M, Egger M, Heller R, Zwahlen M. (2008). Body-mass index and incidence of cancer: a systematic review and meta-Analysis of prospective observational studies. Lancet 371: 569-578.
35. Salvesen H, Iversen O, Akslen L. (1998). Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 4: 2779-2785.
36. Salvesen HB, Iversen OE, Akslen LA. (1999). Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17: 1382-1390.
37. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H. (2013). Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One 8: e61537.
38. Schuler KM, Rambally BS, Difurio MJ, Sampey BP, Gehrig PA, Makowski L, Bae-Jump VL. (2015). Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 4: 161-173.
39. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA. (2004). Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 44: 472-479.
40. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. (1981). Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12: 235-246.
41. Worsley R, Jane F, Robinson PJ, Bell RJ, Davis SR. (2014). Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Climacteric 18: 270-277.
42. Zaino RJ, Brady WE, Todd W, Leslie K, Fischer EG, Horowitz NS, Mannel RS, Walker JL, Ivanovic M, Duska LR. (2014). Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol 33: 543-553.
43. Zakikhani M, Blouin MJ, Piura E, Pollak MN. (2010). Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-279.
44. Zakikhani M, Dowling R, Fantus I, Sononberg N, Pollak M. (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273.